接受化疗治疗的骨和软组织肉瘤患者的疲劳,功能能力和生活质量:一项观察性研究
Mattia Morri1, Riccardo Boccomino1, Eugenio Brruku1
1IRCCS Istituto Ortopedico Rizzoli, Servizio di Assistenza Infermieristico, Tecnico e della Riabilitazione (SAITeR), via G.C.Pupilli, 1, 40136, Bologna, Italy.
概括
疲劳综合征对接受骨和软组织肉瘤化疗的患者产生重大影响. 非吸烟状态,较高的BMI和功能能力是影响疲劳的关键因素,突出了早期干预的必要性.
科学领域:
- 在瘤学瘤学.
- 临床医学 临床医学
- 患者报告的结果
背景情况:
- 骨和软组织肉瘤在化疗期间存在独特的挑战.
- 疲劳,生活质量和功能能力是癌症治疗期间患者护理的关键方面.
研究的目的:
- 为了评估疲劳综合征,生活质量和功能能力在肉瘤患者在化疗的前六个月.
- 确定与这些结果相关的预后因素.
主要方法:
- 一项前性观察性研究包括了98名患者,他们在2019年7月至2021年4月期间开始化疗.
- 使用简要疲劳清单 (BFI) 评分来评估疲劳.
- 使用EORTC QLQ-C30和TESS分数,分别在基线和六个月测量了生活质量和功能能力.
主要成果:
- 36%的患者报告中度至严重的疲劳.
- 全球生活质量和功能能力 (TESS评分) 的平均增长分别为3.9分和8.5分.
- 吸烟状态,较高的体重指数 (BMI) 和功能能力受损被确定为疲劳的独立预测因素.
结论:
- 疲劳综合征在接受化疗的肉瘤患者中很普遍.
- 非吸烟者身份,较高的BMI和更好的功能能力可能与疲劳减少有关.
- 早期疲劳查,患者教育和量身定制的有氧运动是推的干预措施.
相关概念视频
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
174
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
174
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


